Original Article
Glucagon-like peptide-1 receptor agonist reduces recurrent cardiovascular risk in overweight/obese patients with type 2 diabetes mellitus complicated with coronary heart disease
Xiaoling Li, Qiuhong Gong, Yali An, Lihong Zhang, Yuanchi Hui, Xiaoxia Shen, Xinxing Feng, Hui Wang, Xiaojue Li, Yanyan Chen
Published 2019-05-27
Cite as Chin J Diabetes Mellitus, 2019, 11(5): 341-346. DOI: 10.3760/cma.j.issn.1674-5809.2019.05.006
Abstract
ObjectiveTo explore the effect of glucagon-like peptide-1 receptor agonist (GLP-1RA) on cardiovascular risk in overweight/obese type 2 diabetic patients complicated with coronary heart disease.
MethodsA retrospective study was proceeded in 200 overweight/obese diabetic patients with coronary heart disease at Fuwai Hospital from October 2010 to October 2016. Patients were divided into GLP-1RA treatment group (n=105) and the conventional treatment group (n=95). Data of body weight,body mass index (BMI), glycated hemoglobin A1c (HbA1c), fasting plasma glucose (FPG) and blood lipids before and after treatment for 6 months or drug withdrawal after 30 months were analyzed. The incidence rates of recurrent cardiovascular events/the cardiovascular risks were also evaluated between these 2 groups. Kruskal-Wallis test was used to compare the continuous variables in non-normal distribution, Student-t test was used to compare the continuous variables in normal distribution,and paired t-test was used to analyze the follow-up data and baseline data. Chi-Square test was used to compare the classified variable between groups. Multivariate Logistic regression analysis was used to analyze the related risk factors of cardiovascular events.
ResultsWeight [(-5.7±4.0) vs (-1.3±2.4)kg], BMI [(-1.9±1.3) vs (-0.4±0.7)kg/m2], HbA1c [(-1.5±1.3)% vs (-0.8±0.6)%] and low density lipoprotein cholesterol after 6-month treatment were significantly decreased in GLP-1RA treatment group than those in conventional treatment group (t=2.42-4.19, all P<0.05). After 30-month following-up, the incidence rates of cardiovascular events in GLP-1RA group were significantly lower than those in conventional treatment group [2.86%(3/105) vs 11.58%(11/95), χ2=4.57, P<0.05]. Compared with conventional treatment group after adjustment of multiple risk factors, the risk of recurrent cardiovascular events in GLP-1RA treatment group was significantly decreased (OR:0.23, 95%CI: 0.06-0.89, P=0.04).
ConclusionShort-term application of GLP-1RA could alleviate body weight, improve glycolipid metabolic disorder, and reduce the risk of recurrent cardiovascular events in overweight/obese type 2 diabetic patients with coronary heart disease.
Key words:
Diabetes mellitus, type 2; Overweight; Obesity; Coronary artery disease; Cardiovascular risk; Glucagon-like peptide-1 receptor agonist
Contributor Information
Xiaoling Li
Peking Union Medical Colllege, Chinese Academy of Medical Science Fuwai Hospital, Beijing 100037, China
Qiuhong Gong
Chinese Academy of Medical Science Fuwai Hospital, Ward 2 of Endocrinology and Cardiovascular Diseases, Beijing 100037, China
Yali An
Chinese Academy of Medical Science Fuwai Hospital, Ward 2 of Endocrinology and Cardiovascular Diseases, Beijing 100037, China
Lihong Zhang
Chinese Academy of Medical Science Fuwai Hospital, Ward 2 of Endocrinology and Cardiovascular Diseases, Beijing 100037, China
Yuanchi Hui
Chinese Academy of Medical Science Fuwai Hospital, Ward 2 of Endocrinology and Cardiovascular Diseases, Beijing 100037, China
Xiaoxia Shen
Chinese Academy of Medical Science Fuwai Hospital, Ward 2 of Endocrinology and Cardiovascular Diseases, Beijing 100037, China
Xinxing Feng
Chinese Academy of Medical Science Fuwai Hospital, Ward 2 of Endocrinology and Cardiovascular Diseases, Beijing 100037, China
Hui Wang
Chinese Academy of Medical Science Fuwai Hospital, Ward 2 of Endocrinology and Cardiovascular Diseases, Beijing 100037, China
Xiaojue Li
Chinese Academy of Medical Science Fuwai Hospital, Ward 2 of Endocrinology and Cardiovascular Diseases, Beijing 100037, China
Yanyan Chen
Peking Union Medical Colllege, Chinese Academy of Medical Science Fuwai Hospital, Beijing 100037, China
Chinese Academy of Medical Science Fuwai Hospital, Ward 2 of Endocrinology and Cardiovascular Diseases, Beijing 100037, China